Tumorigenic de-differentiation: the alternative splicing way

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The mechanism of acquisition of tumorigenic properties by somatic cells at the onset of cancer and later during relapse is a question of paramount importance in cancer biology. We have recently discovered a Muscleblind like-1 (MBNL1)-driven alternative-splicing mediated mechanism of tumorigenic de-differentiation that is associated with poor prognosis, relapse and metastasis in common cancer types.

Cite

CITATION STYLE

APA

Ray, D., & Epstein, D. M. (2020). Tumorigenic de-differentiation: the alternative splicing way. Molecular and Cellular Oncology, 7(6). https://doi.org/10.1080/23723556.2020.1809959

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free